Market capitalization | $3.60b |
Enterprise Value | $3.94b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 5.69 |
P/S ratio (TTM) P/S ratio | 5.20 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 29.20% |
Revenue (TTM) Revenue | $692.26m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
24 Analysts have issued a Guardant Health, Inc. forecast:
24 Analysts have issued a Guardant Health, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 692 692 |
29%
29%
|
|
Gross Profit | 417 417 |
29%
29%
|
|
EBITDA | -472 -472 |
1%
1%
|
EBIT (Operating Income) EBIT | -515 -515 |
1%
1%
|
Net Profit | -512 -512 |
19%
19%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Guardant Health, Inc. is a precision oncology company, which engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2012 and is headquartered in Redwood City, CA.
Head office | United States |
CEO | Helmy Eltoukhy |
Employees | 1,779 |
Founded | 2012 |
Website | www.guardanthealth.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.